Cellectar Biosciences, Inc. — filing summary
Filing identity and period: The supplied filing is Novelos Therapeutics, Inc.’s Form 10-K for the fiscal year ended December 31, 2012, filed March 28, 2013. It is not a filing under the name Cellectar Biosciences, Inc.; Novelos acquired Cellectar, Inc. in 2011, and the transaction was accounted for as a reverse acquisition, with Cellectar treated as the accounting acquirer. The 2011 comparison includes Cellectar’s results only from January 1 through April 8 and the combined company thereafter, so it is not fully comparable with 2012.
Business context and development outlook
The company is a development-stage oncology company with no significant revenue from planned operations. Its focus is Cellectar’s phospholipid ether technology and three principal candidates: LIGHT, a PET imaging agent; HOT, a radiotherapeutic; and GLOW2, a preclinical optical imaging agent. Development of legacy compounds NOV-002 and NOV-205 was suspended. The company reported no product revenue and expects operating losses to continue.
- LIGHT investigator-sponsored Phase 1-2 studies were ongoing across multiple solid-tumor indications. Small early patient cohorts showed tumor uptake and no observed adverse safety signals; these preliminary findings do not establish efficacy.
- HOT’s Phase 1b dose-escalation study had completed its second cohort at 25 mCi/m², with no dose-limiting or sub-dose-limiting toxicities reported in that cohort. The third cohort was initiated at 37.5 mCi/m².
- GLOW2 remained preclinical. The company expected to submit an IND in fourth-quarter 2013, subject to additional funding. Company-sponsored LIGHT Phase 2 trials were planned for 2014, also subject to funding.
Financial performance and position
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Revenue from planned operations | No significant revenue | No significant revenue |
| Research and development expense | $5.123 million | $3.599 million |
| General and administrative expense | $3.632 million | $2.692 million |
| Total operating expenses / operating loss | $8.755 million | $7.038 million |
| Net loss | $8.797 million | $7.435 million |
| Net loss attributable to common stockholders | $9.340 million | $7.435 million |
| Cash used in operating activities | $6.585 million | $5.970 million |
- R&D increased 42.3%, mainly due to higher LIGHT and HOT clinical-trial and manufacturing costs, research activity, staffing and stock compensation. G&A increased 34.9%, principally due to stock compensation, salaries and public-company services.
- The 2012 common-stockholder loss includes a $543,359 deemed dividend from extending certain warrants; it is excluded from net loss. Operating margins are not meaningful because the company had no significant operating revenue.
- At December 31, 2012, cash and cash equivalents were $4.678 million, versus $5.506 million a year earlier. Restricted cash totaled $2.055 million, including $2.0 million contractually designated for a proposed LIGHT manufacturing facility and $55,000 associated with the Wisconsin lease.
- Working capital was approximately $4.398 million; stockholders’ equity was $10.158 million. Total liabilities were approximately $1.320 million, including $450,000 in long-term Wisconsin Department of Commerce notes, due through 2017. The notes carry 2% interest, with payments scheduled to begin in 2015.
- June 2012 public and November 2012 private offerings generated net proceeds of approximately $4.871 million and gross proceeds of $2.0 million, respectively; the latter proceeds were restricted for the proposed facility. Warrant exercises generated a further $1.088 million in 2012.
Material changes, risks, and unusual items
- Management said December 31, 2012 cash, together with approximately $5.0 million net proceeds from a February 20, 2013 public offering, was expected to fund budgeted operations through October 2013. Further funding was required beyond that point; the company said it had not entered financing negotiations and gave no assurance of obtaining capital.
- The auditor issued an unmodified opinion on the financial statements but included a going-concern explanatory paragraph, citing recurring losses and substantial doubt about the company’s ability to continue. The statements contain no adjustments for the outcome of that uncertainty.
- The February 2013 offering raised $5.5 million gross through common shares and warrants, creating potential dilution. At March 25, 2013, 57,397,997 common shares were outstanding, compared with 46,397,997 at year-end 2012.
- The company was evaluating contract manufacturing for larger-scale LIGHT supply and said it was not then pursuing construction of the facility funded by restricted proceeds. LIGHT manufacturing relied on a University of Wisconsin arrangement due to expire in June 2013, with a fee-based arrangement under negotiation.
- Clinical development, regulatory approval, manufacturing scale-up, reimbursement, intellectual-property rights and the ability to raise capital are material risks. The company had no commercial products, and its pipeline remained at early clinical or preclinical stages.
- The NOV-002 securities class action was dismissed with prejudice in June 2012, and the plaintiffs did not appeal by the deadline. A separate dispute with ZAO BAM concerning legacy compounds remained on appeal; management did not expect these matters to materially affect financial position, results or cash flows.
- Management reported effective internal control over financial reporting and effective disclosure controls as of December 31, 2012. The auditor did not attest to internal control effectiveness.
Most important facts for investors to verify
- Whether post-offering cash and actual spending supported the stated runway through October 2013, and what financing was subsequently obtained.
- Current clinical-trial status and complete safety and efficacy data for LIGHT and HOT, beyond the preliminary, small-cohort results described here.
- Whether LIGHT manufacturing arrangements and GLOW2 IND-enabling work progressed as planned, including the use of the $2.0 million restricted balance.
- The fully diluted share count and potential dilution from outstanding warrants, options and subsequent financing instruments.
- The status and financial exposure of the ZAO BAM appeal and any other contingencies or commitments.